中國電信(601728.SH):共計573.8億股限售股將於2月20日鎖定期屆滿並上市流通
格隆匯2月13日丨中國電信(601728.SH)公佈,本次上市流通的限售股爲公司首次公開發行前公司控股股東電信集團已持有的股份,共計573.8億股,佔公司總股本的62.7023%。該部分限售股原鎖定期爲公司A股股票在上交所上市交易之日起36個月,因公司股票在上市後6個月內存在連續20個交易日收盤價均低於公司首次公開發行A股發行價4.53元/股的情形,依照股份鎖定期安排及相關承諾,公司控股股東電信集團持有的公司股份在原鎖定期基礎上自動延長6個月,將於2025年2月20日鎖定期屆滿並上市流通。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.